Citations

Clear

2236 citation(s) found for "Ju, Angela".

Urine Mast Cell Mediator Levels in the Pediatric Population with and without Allergic Disease Stratified by Age and Gender: A Novel Diagnostic Insight
Manian, Deepti Vellaichamy , Butterfield, Joseph H., Meeusen, Jeffrey W. , Mattke, Angela, Ravi, Anupama, Vellaichamy Manian, Deepti , Butterfield, Joseph H.

Mayo Clinic

Allergy | April 18, 2026 | Volume: 81 | Issue: 8 | Pages: 2976-2978

10.1111/all.70343 | PMID 41998828 Get It

Abstract LB205: Dissociation between prediagnostic imaging phenotype and tumor biology defines the early detection challenge in pancreatic ductal adenocarcinoma
Bhinder, Khurram Khaliq , Mukherjee, Sovanlal , Jadoon, Ahmed Khan , Feng, Ziding, Goenka, Ajit H. , Zarrintan, Armin , Ammirabile, Angela , Ziding, Feng, Chari, Suresh T.

Mayo Clinic

Cancer Research | April 17, 2026 | Volume: 86 | Issue: 8_Supplement | Pages: LB205-LB205

10.1158/1538-7445.am2026-lb205 Get It

Abstract Background: Early detection is the most potent strategy to improve survival in PDA, but its success hinges on an unresolved question: does radiologically invisible disease represent biologically early or indolent disease, or established malignancy beneath the threshold of detection? We leveraged prediagnostic CTs—incidental scans obtained 3-36 months prior to diagnosis without a focal mass—to define the relationship between imaging phenotype and tumor biology. Methods: From a multi-institutional pool of 5,046 biopsy-confirmed PDAs, we assembled a cohort of 346 prediagnostic CTs, which were independently evaluated by three radiologists using a standardized protocol. Based on majority vote, CTs were dichotomized into imaging-occult (IO) (normal pancreas) and imaging-apparent (IA) (abnormal pancreas with indirect signs such as focal atrophy, duct dilatation, etc.) groups. Tumor size and metastases (M) at diagnosis, and overall survival (OS) were compared using multivariable linear (size), logistic (M1), and Cox proportional hazards (OS) models, adjusting for lead time to diagnosis, age, sex, diabetes, CA 19-9, and surgical resection status, to isolate the independent biological relevance of the imaging phenotype. Results: IO phenotype was seen in 150 patients (mean age 66.7±11.2; 37.3% females) while 196 had IA phenotype (mean age 69.9±10.6; 49.5% females). Median lead time was 396 days (range: 90-1088) with the IA group being enriched in 3-12-month lead time (57.7% vs 33.3%; p<0.001). Both groups had comparable diabetes rates (IA 33.2% vs IO 32.7%; p=1.0), median CA 19-9 (IA 193 vs IO 322 U/mL; p=0.41), and surgical resection (IA 38.3% vs IO 38.0%; p = 1.0). While unadjusted mean tumor size at diagnosis was larger in IA group (3.8 cm vs 3.2 cm), there was no difference after adjusting for clinical factors (-7.1% difference; 95% CI: -17.2, 4.2; p=0.21). Metastases were also comparable (M rate: IA 22.4% vs IO 27.3%; adjusted OR 0.97; 95% CI: 0.50, 1.88; p=0.93). Adjusted Cox models demonstrated equivalent OS (median: 18.7 vs 17.6 months; HR 1.06; p=0.66), which persisted even when stratified by surgical status (HR 1.07; 95% CI: 0.83, 1.38; p=0.61). Even in the critical 3-12 months lead time (n=163), OS remained equivalent (HR 0.89; p=0.62), and groups did not differ in either tumor size (-6.4%; 95% CI: -22.4, 12.9; p=0.49) or metastases (OR 0.48; 95% CI 0.14, 1.59; p=0.23). Conclusions: A normal-appearing pancreas on prediagnostic imaging is common yet signifies neither early nor indolent disease—it harbors PDA biologically equivalent to the imaging-apparent pancreatic phenotype. Because the disease at this stage lies beyond human perceptual capacity, AI augmentation represents the only potential path to realizing the survival benefit of early detection. Citation Format: Khurram Khaliq Bhinder, Sovanlal Mukherjee, Armin Zarrintan, Angela Ammirabile, Ahmed Khan Jadoon, Ziding Feng, Suresh T. Chari, Ajit H. Goenka. Dissociation between prediagnostic imaging phenotype and tumor biology defines the early detection challenge in pancreatic ductal adenocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(8_Suppl):Abstract nr LB205.
Operative Strategies and Wound Complications for Morel-Lavallee Injuries Undergoing Excisional Debridement: A Pacific Coast Surgical Association Multicenter Study
Nguyen, Peter , Grigorian, Areg , Costantini, Todd, Santorelli, Jarrett, Husen, Lilian Von, Inaba, Kenji, Schellenberg, Morgan, Stephens, Daniel, Chaar, Mohamad Abou, Mahmoud, Khalid, Schreiber, Martin, Minoza, Karen, Underwood, Samantha, Biffl, Walter, Lü, Ning , Bayat, Dunya, Edwards, Sara, Tillou, Areti, Zheng, Dennis J. , Plevin, Rebecca E. , Stein, Deborah, Smith, Juliana, Sonntag, Cheyenne C., Callcut, Rachael A. , Furlong, Harly, Graeff, Leonardo Weber, Trevizo, Eric, Cochran-Yu, Meghan, Duncan, Thomas, Diaz, Graal , Neville, Angela , Balan, Naveen , Siletz, Anaar, Ley, Eric, Park, Greigory, Alexander, Juliet, Johnson, Arianne, Cotton-Betteridge, Aaron , Smith, Maren, Alvarez, Claudia, Scolaro, John, Aryan, Negaar , Nahmias, Jeffry, Nguyen, Peter D , Abou Chaar, Mohamad , Lu, Ning , Coimbra, Raul , Balan, Naveen , Alvarez, Claudia , Aryan, Negaar , Costantini, Todd W. , Dilday, Joshua C. , Inaba, Kenji , Schellenberg, Morgan A. , Stephens, Daniel, Chaar, Mohamad K. Abou , Minoza, Karen , Biffl, Walter L. , Tillou, Areti , Kim, Hannah , Graeff, Leonardo W., Duncan, Thomas K. , Kim, Dennis S. , Siletz, Anaar E., Ley, Eric J. , Scolaro, John A. , Nahmias, Jeffry T.

Mayo Clinic

The American Surgeon™ | April 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/00031348261443695 | PMID 41990323 Get It

Morel-Lavallee lesions (MLLs) are traumatic closed degloving injuries with operative intervention (OI), especially excisional debridement, remaining the mainstay of treatment. However, high-quality evidence describing operative techniques and outcomes remains limited. This study aimed to characterize current OI practices and associated outcomes, especially among patients undergoing excisional debridement, hypothesizing an increased risk of wound complications with this approach for MLLs. Methods This prospective (2021-2024), multicenter, observational study was conducted across 15 trauma centers and included patients diagnosed with MLL who underwent OI. The association between operative technique (eg, excisional debridement) and the primary outcome of wound complications was evaluated. Wound complications were defined as cellulitis, deep wound infection, skin necrosis, necrotizing soft tissue infection (NSTI), and/or organized hematoma. Results Of 88 MLL patients undergoing OI, 36 (40.9%) had excisional debridement, with 4 (11.1%) limited excision to skin, 20 (55.6%) extended to subcutaneous tissue, and 12 (33.3%) down to muscle. Excisional debridement had higher rates of skin necrosis (22.2% vs. 1.9%, P = .002). Although overall rates of wound complications were statistically similar between cohorts (33.3% vs. 17.3%, P = .098), univariate analysis demonstrated excisional debridement had increased risk of wound complications (OR 2.52, CI 1.07-5.97, P = .035). Conclusion This prospective multicenter study over three years demonstrated that a fifth of MLLs undergoing excisional debridement developed postoperative skin necrosis. Excisional debridement also had a more than two-fold increased risk of wound complications compared to other OIs. These findings underscore the importance of investigating alternative operative techniques, such as incision and drainage or minimally invasive debridement methods.
Diagnostic utility of immunofixation and free light chain assay in AL amyloidosis: a systematic review and meta-analysis
Azzam, Muayad , Hamarsha, Qais , Kawtharany, Hassan , Nazzal, Jamil, Alkhader, Aseel, Khraise, Tala, AlMasri, Mohammad M., Zeid, Hadi K. Abou, Alwan, Iktimal, Jaber, Nour, Seftel, Matthew D. , Aguirre, M A, Boedicker, Deborah , Bumma, Naresh , Comenzo, Raymond, Dasgupta, Noel R, Torre, Alfredo De La, Jamal, Faizi , Khouri, Jack , Raza, Shahzad, Sarswat, Nitasha , Shaikh, Hira , Singh, Daulath , Kukreti, Vishal, Zeid, Hadi Khaled Abou , Aguirre, María Adela , Abou Zeid, Hadi Khaled , Aguirre, Maria Adela , Carroll, Antonia S , Cook, Joselle M , Dispenzieri, Angela , Jamal, Faizi , Khouri, Jack , Picken, Maria M. , Leung, Nelson , Sanchorawala, Vaishali , Sarswat, Nitasha , Mustafa, Reem A , Kawtharany, Hassan , Shaikh, Hira , Carroll, Antonia , Comenzo, Raymond L. , Cook, Joselle , Dispenzieri, Angela , Raza, Shahzad, Leung, Nelson , Kukreti, Vishal

Mayo Clinic

Blood Advances | April 14, 2026 | Volume: 10 | Issue: 15 | Pages: 5293-5307

10.1182/bloodadvances.2025019530 | PMID 41979328 Get It

Abstract In this systematic review, we aimed to assess the sensitivity of serum immunofixation (SIFE), urine immunofixation (UIFE), and serum free light chain (sFLC) in detecting plasma cell dyscrasia associated with light chain (AL) amyloidosis. We searched the literature using PubMed, Embase, and CENTRAL databases since inception through March 2024. We included studies reporting the diagnostic accuracy of immunofixation and/or sFLC in patients with AL amyloidosis. We used the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach to assess the certainty of the evidence and QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies-2) to assess the risk of bias. After deduplication, 29 237 records were screened, and 44 studies (n = 18 071) were included. For the meta-analysis, 28 studies reported sensitivity for SIFE (n = 3390), 24 studies for UIFE (n = 2830), 19 studies for SIFE and UIFE (n = 2819), 21 studies for sFLC ratio (n = 3678), 6 studies for SIFE and sFLC ratio (n = 372), 3 studies for UIFE and sFLC ratio (n = 242), and 10 studies for all 3 tests (n = 1430). Pooled sensitivities were as follows: SIFE, 0.68 (95% confidence interval [CI], 0.62-0.73); UIFE, 0.77 (95% CI, 0.72-0.81); SIFE and UIFE, 0.89 (95% CI, 0.84-0.93); and sFLC ratio, 0.82 (95% CI, 0.78-0.86). When SIFE, UIFE, and sFLC ratio were combined, the sensitivity reached 0.99 (95% CI, 0.96-1.00). The high sensitivity of combining SIFE, UIFE, and sFLC ratio supports their use as a reliable initial testing strategy to raise suspicion for AL amyloidosis and guide decisions regarding future diagnostic modalities.
Building capacity for translational team science: digital badging as a pathway to professionalization
Glauber, Kristine M. , Sweeney, Whitney A. , Boguslav, Mayla R., Fox, Andrew T., Hartstein, Madison, Hildreth, Laura , Lee-Chavarria, Diana , McCormack, Wayne T. , Mendell, Angela, Molano, Jennifer Rose V. , Risser, Heather J. , Billings, Heather A, Billings, Heather , Boguslav, Mayla R. , Lobb, Rebecca , Mendell, Angela M. , Brasier, Allan R.

Mayo Clinic

Frontiers in Psychology | April 10, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.3389/fpsyg.2026.1771863 | PMID 42039008 Get It

Effective translation relies on high performance teams integrating diverse disciplines to bring new drugs, medical devices, diagnostics or behavioral interventions into improved health. Despite substantial advancements informed by the Science of Team Science (SciTS), challenges remain in effective translational team (TT) operations, while limited institutional, scholarly, and practitioner legitimacy of team science expertise constrains efforts to address them. Here, we describe an essential member of the TT, the Team Science Professional (TSP). Serving as a team educator and facilitator of team interventions, the TSP plays a pivotal role in facilitating effective team performance. Current challenges faced by this nascent profession are defining career pathways and establishing competencies needed for expert performance. To address these challenges, the authors, representing a spectrum of academic universities organized as a special interest group (SIG) of the Association of Clinical and Translational Science (ACTS), propose a suite of individualized, standardized and pathway-selective micro-credentials (digital badges). Digital badges in “Team Science (TS) Fundamentals,” “TS Practitioner,” “TT Trainer” and “TT Intervention Expert” are described, along with preliminary feasibility and usability evaluations of the submission process. These stackable credentials provide a customizable, portable recognition of skills and help advance career pathways for TSPs. In so doing, the Digital Badge Initiative will enhance the capacity of translational science “Hubs” such as those supported by Clinical and Translational Science Awards to conduct effective and rigorous translation. Moving forward, the ACTS TSP SIG will be examining the impact of digital badging on standardization and its effect on career recognition and retention.
Determinants of gastrointestinal disease burden and survival in systemic AL amyloidosis
Steinhardt, Maximilian , Muchtar, Eli , Kourelis, Taxiarchis , Warsame, Rahma , Mauermann, Michelle Lynn, Buadi, Francis K. , Dingli, David, Leung, Nelson , Cook, Joselle , Go, Ronald S., Hayman, Suzanne R. , Gonsalves, Wilson I, Kapoor, Prashant , Zanwar, Saurabh , Hellou, Tamer , Tan, Melinda S.Y., Halawi, Houssam, Fonder, A C, Hobbs, Miriam, Abdallah, Nadine , Lin, Y., Siddiqui, Mustaqeem, Kyle, R., Einsele, Hermann, Rajkumar, S Vincent, Kumar, Shaji , Steinhardt, Maximilian , Binder, Moritz , Hellou, Tamer , Fonder, Amie , Abdallah, Nadine H , Siddiqui, Mustaqeem A , Kortüm, Martin , Kumar, Shaji K , Gertz, Morie A , Dispenzieri, Angela , Leung, Nelson , Muchtar, E , Buadi, Francis K , Cook, Joselle M , Mauermann, Michelle L. , Dingli, David , Go, Ronald S. , Gonsalves, Wilson I. , Binder, Moritz , Halawi, Houssam , Siddiqui, Mustaqeem , Kortüm, K. Martin , Einsele, Hermann , Rajkumar, S. Vincent , Gertz, Morie A. , Dispenzieri, Angela

Mayo Clinic

Blood Advances | April 9, 2026 | Volume: 10 | Issue: 11 | Pages: 4009-4019

10.1182/bloodadvances.2026019722 | PMID 41954624 Get It

Abstract Gastrointestinal (GI) involvement is a clinically relevant but undercharacterized manifestation of systemic light chain amyloidosis (AL). We aimed to define the clinical spectrum, histologic patterns, and outcomes of symptomatic GI involvement in AL. We retrospectively analyzed 4396 patients with AL from 2010 to 2024, of whom 521 (11.9%) had provider-attributed symptomatic GI involvement; 66% had biopsy-proven GI AL. Symptoms most commonly included early satiety (61%), bowel irregularities (58%), nausea (35%), abdominal pain (28%), and dysphagia (23%). Autonomic neuropathy was frequent (43% clinician attributed; 23% via autonomic reflex testing) and contributed to dysmotility-related symptoms, often without GI biopsy positivity. Among 747 GI biopsies, mucosal infiltration predominated (71%) and was associated with bleeding (22% vs 9%), cachexia, and inferior survival, whereas vascular involvement was associated with lower bleeding risk. Combined involvement of mucosa, submucosa, and vessels conferred the worst prognosis (median overall survival [mOS], 2.4 vs 5.1 vs 7.8 years for 3 vs 2 vs 1 layer); mOS was 6.8 years and was primarily driven by cardiac stage and hematologic response (very good partial response [VGPR] or better: hazard ratio, 0.20; 95% CI 0.13-0.32), with more favorable outcomes in patients with isolated GI involvement. Cachexia and persistent diarrhea were the main drivers of morbidity, need for nutritional support, and GI-related mortality (odds ratio, 2.7 for the combined end point). GI bleeding rarely recurred after achieving VGPR or better. Overall, mucosal involvement, cachexia, and dysmotility define clinically meaningful GI AL and support systematic assessment of autonomic dysfunction as well as evaluation of the need for nutritional support as a GI-specific end point for AL trials.
Inpatient continuous thalamic stereo-electroencephalography stimulation in the evaluation of focal epilepsy: illustrative case
Lerma, Bruno Hidalgo Monroy, Makhoul, Ghassan S. , Reda, Anas, Cavender, Addison C. , Doss, Derek J. , Withers, C Price, Funk, Chadd, Crudele, Angela, Englot, Dario J, Lerma, Bruno Hidalgo Monroy , Withers, C Price , Hidalgo Monroy Lerma, Bruno , Wang, Kate , Doss, Derek J , Johnson, Graham W. , Englot, Dario J.

Mayo Clinic

Journal of Neurosurgery: Case Lessons | April 8, 2026 | Volume: 11 | Issue: 14 | Pages: No page available

10.3171/case25947 | PMID 41941831 Get It

BACKGROUND In patients with drug-resistant epilepsy (DRE) who are not candidates for resective surgery, thalamic neuromodulation targeting structures such as the anterior nucleus of the thalamus (ANT), centromedian nucleus (CM), and pulvinar (PUL) has emerged as a promising therapy. The clinical investigation of these targets’ efficacy and side effect profiles is ongoing, complicating discussions between neurosurgeons, neurologists, and patients. The implementation of single-pulse and continuous stimulation protocols to conduct patient-specific side effect screens and generate prognostic biomarkers could offer guidance for target selection. OBSERVATIONS A 32-year-old male with extensive polymicrogyria and DRE underwent stereo-electroencephalography (SEEG) with multisite thalamic sampling to inform neuromodulation target selection. Single-pulse stimulation was conducted to screen for acute sensorimotor effects, followed by continuous (12- to 24-hour) stimulation using clinically relevant parameters. Intolerable paresthesia occurred during CM single-pulse stimulation, leading to its exclusion as a target. Single-pulse and continuous stimulation of the ANT and PUL were well tolerated. PUL stimulation offered superior suppression of epileptiform discharges during sleep. LESSONS These findings meaningfully informed the selection of the PUL as a neuromodulation target. This case illustrates the safety, feasibility, and utility of patient-specific single-pulse and continuous stimulation assessments during SEEG monitoring to evaluate efficacy and tolerability prior to chronic neuromodulation, particularly for novel thalamic targets. https://thejns.org/doi/10.3171/CASE25947
Risk of AL Amyloidosis is Associated with Degree of Free Light Chain Elevation and Duration of Exposure
Steinhardt, Maximilian , Muchtar, Eli , Kourelis, Taxiarchis , Warsame, Rahma, Buadi, Francis K. , Dingli, D., Leung, Nelson , Cook, Joselle , Go, Ronald S. , HAYMAN, Suzanne, Kapoor, Prashant , Zanwar, Saurabh , Hellou, Tamer , Fonder, Amie , Hobbs, Miriam, Abdallah, Nadine , Lin, Y., Siddiqui, Mustaqeem, Kyle, R., Kortüm, Martin K., Kumar, Shaji , Dingli, David , Dispenzieri, Angela , Steinhardt, Maximilian , Muchtar, E , Kourelis, Taxiarchis , Buadi, Francis K , Dingli, David , Leung, Nelson , Cook, Joselle M , Go, Ronald S , Gonsalves, Wilson , Kapoor, Prashant , Zanwar, Saurabh S , Binder, Moritz , Hellou, Tamer , Abdallah, Nadine H , Lin, Yi , Siddiqui, Mustaqeem A , Kortüm, Martin , Einsele, Hermann , Rajkumar, S Vincent , Kumar, Shaji K , Gertz, Morie A , Dispenzieri, Angela , Warsame, Rahma , Hayman, Suzanne R. , Gonsalves, Wilson I. , Binder, Moritz , Siddiqui, Mustaqeem , Kortüm, K. Martin , Rajkumar, S. Vincent , Gertz, Morie A.

Mayo Clinic

No container title available | April 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9227260/v1 | PMID 41994108 Get It

Abstract Systemic light chain amyloidosis (AL) arises from monoclonal immunoglobulin light chains, but determinants of progression from precursor states remain poorly defined. In a cross-sectional cohort comprising 1950 systemic AL patients diagnosed 2010-2024, 258 (13.2%) patients with a previously diagnosed plasma cell disorder (PCD) were compared to patients with no prior PCD diagnosis. Patients with monoclonal gammopathy of undetermined signficance (MGUS) and smoldering multiple myeloma (SMM) in the former group had lower difference between involved and uninvolved FLCs (dFLC), higher M-protein, and lower rates of t(11;14) at AL diagnosis. Patients developing AL from SMM had a shorter time to AL (median 34.2 versus 61.3 months) and higher dFLC (median 28.9 versus 11.0 mg/dl) compared to those from MGUS. Patients developing AL after known multiple myeloma (MM) or lymphoplasmacytic lymphoma (LPL) commonly lacked deep hematologic response before AL (≤ very good partial response in 78% of MM, 100% of LPL patients). We additionally studied longitudinally followed cohorts of 3,966 MGUS and 426 (SMM) patients with longitudinal FLC measurements and matched follow-up, in which 1.8% of MGUS and 7.2% of SMM patients developed AL. Those patients who developed AL showed markedly higher dFLC at MGUS/SMM diagnosis and more frequent λ restriction and rates of t(11;14). Higher dFLC was associated with progressively earlier AL development; a 10% cumulative risk occurred at 20 months for patients with a dFLC >80 mg/dL but was not reached if dFLC <10 mg/dL at an estimated median follow-up of 86 months. In multivariable analysis, dFLC >6.4 mg/dL (HR 11.3) and λ isotype (HR 3.6) independently predicted AL, whereas heavy chain secretion was associated with lower risk (HR 0.2 for IgG). These findings indicate that AL risk is primarily driven by cumulative light chain exposure, refining our knowledge of AL pathophysiology and providing guidance for follow-up of patients with elevated dFLC.
Breakpoints in Alzheimer's disease biomarkers and cognition across the aging spectrum: The Mayo Clinic Study of Aging
Hu, Mingzhao, Knopman, David S., Therneau, Terry, Fought, Angela J. , Hofrenning, Ekaterina I. , Lowe, Val J., Petersen, Ronald C., Jack, Clifford R., Mielke, Michelle M., Vemuri, Prashanthi, Graff‐Radford, Jonathan, Hofrenning, Ekaterina, Graff-Radford, Jonathan , Hu, Mingzhao, Knopman, David S. , Therneau, Terry, Lowe, Val J. , Petersen, Ronald C. , Algeciras‐Schimnich, Alicia , Jack, Clifford R. , Stricker, Nikki H. , Mielke, Michelle M. , Vemuri, Prashanthi , Graff‐Radford, Jonathan

Mayo Clinic

Alzheimer's & Dementia | April 7, 2026 | Volume: 22 | Issue: 4 | Pages: No page available

10.1002/alz.71227 | PMID 41944335 Get It

Abstract INTRODUCTION We examined when Alzheimer's disease biomarkers become informative by identifying age‐related breakpoints with slope‐changing trajectories. METHODS In 2082 Mayo Clinic Study of Aging participants, we modeled plasma amyloid beta (Aβ)42/40, phosphorylated tau (p‐tau)181, glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), amyloid/tau positron emission tomography (PET), hippocampal volume (HVa), and global cognition. Generalized additive models described age trends; Davies' test and piecewise linear regression estimated breakpoints. A C2N subsample ( n = 462) provided mass‐spectrometry plasma markers (p‐tau181, p‐tau217, their ratios, Aβ42/40). RESULTS In the full cohort, Aβ42/40, HVa, and cognition declined with age; p‐tau181, NfL, GFAP, and amyloid/tau PET increased. We observed single breakpoints (years, 95% CI): GFAP 68.1 (63.5–71.8), NfL 70.7 (65.9–75.6), p‐tau181 67.2 (60.3–70.3), amyloid PET 62.3 (56.2–69.3), HVa 68.1 (63.1–71.9), cognition 59.8 (55.4–66.0); tau PET showed none. In the mass‐spectrometry subset, p‐tau217 and p‐tau181 broke at 72.6; their ratios and Aβ42/40 showed no breakpoints. DISCUSSION Breakpoints cluster near late midlife, suggesting windows for screening and monitoring.